Atopic Dermatitis (Eczema) clinical trials at UCSF
5 in progress, 2 open to eligible people
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
open to eligible people ages 18 years and up
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
San Francisco, California
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
open to eligible people ages 13 years and up
Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
San Francisco, California
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Sorry, in progress, not accepting new patients
The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
San Francisco, California and other locations
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Sorry, in progress, not accepting new patients
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Fresno, California and other locations
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Sorry, in progress, not accepting new patients
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
San Francisco, California
Our lead scientists for Atopic Dermatitis (Eczema) research studies include Wilson Liao Tina Bhutani.
Last updated: